Previous scientific studies have shown that “cellular pharmacodynamics of immunosuppressive drugs is an efficient strategy to predict the clinical efficacy of drugs in many immunological disorders and organ transplantations. Unexpectedly large individual deviations in PBMC sensitivity to the drugs, paralleled with deviations in the clinical efficacy of the drugs have been observed in most cases of immunological disorders”
“Therefore, the examination in vitro of drug sensitivity before drug administration can be a valuable tool to predict the clinical efficacy of drugs in these patients” (Hirano T, 2007)
The logic behind the development of the IMMUNOBIOGRAM® is the same one as in the antibiograms. A pharmacodynamic in vitro bioassay to evaluate the utility of different antibiotics to treat a specific infection in a patient. Antibiograms are extensively used in clinical practice, as they are very valuable in guiding antimicrobial therapy for each patient. An antibiogram provides the profile of susceptibility or resistance patterns of pathogens to antimicrobials commonly used.
The IMMUNOBIOGRAM® has been designed to test the patients´ sensitivity/resistance profile to each immunosuppressant. It is a tool that, taken together with other important variables, can help physicians to make more precise therapeutic decisions.
